Role of allergen immunotherapy and biologics in allergic diseases

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2024-10-01 DOI:10.1016/j.coi.2024.102494

Xiaoying Zhou , Elisabeth M Simonin , Youn S Jung , Stephen J Galli , Kari C Nadeau

{"title":"Role of allergen immunotherapy and biologics in allergic diseases","authors":"Xiaoying Zhou , Elisabeth M Simonin , Youn S Jung , Stephen J Galli , Kari C Nadeau","doi":"10.1016/j.coi.2024.102494","DOIUrl":null,"url":null,"abstract":"<div><div>The rise in the prevalence of allergic diseases has become a global health burden. Allergic diseases are a group of immune-mediated disorders characterized by IgE-mediated conditions resulting from a type 2 helper T cell (Th2)-skewed immune response. This review aims to comprehensively summarize recent research on the roles of allergen immunotherapy (AIT) and biologics in allergic diseases. Specifically, we review the mechanisms of AIT and biologics in modulating innate and adaptive immunity involved in allergic disease pathogenesis, as well as their safety and efficacy in the treatment of allergic diseases. We also discuss current new AIT strategies such as recombinant allergen-based vaccines and allergen extract nanoencapsulation. Further research is needed to understand immune tolerance mechanisms beyond the Th2 pathway and to characterize immunological changes in responders and nonresponders to AIT or biologics. This additional research may uncover new targets for monitoring treatment responses and developing personalized treatment strategies for allergic diseases.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"91 ","pages":"Article 102494"},"PeriodicalIF":6.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791524000840","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The rise in the prevalence of allergic diseases has become a global health burden. Allergic diseases are a group of immune-mediated disorders characterized by IgE-mediated conditions resulting from a type 2 helper T cell (Th2)-skewed immune response. This review aims to comprehensively summarize recent research on the roles of allergen immunotherapy (AIT) and biologics in allergic diseases. Specifically, we review the mechanisms of AIT and biologics in modulating innate and adaptive immunity involved in allergic disease pathogenesis, as well as their safety and efficacy in the treatment of allergic diseases. We also discuss current new AIT strategies such as recombinant allergen-based vaccines and allergen extract nanoencapsulation. Further research is needed to understand immune tolerance mechanisms beyond the Th2 pathway and to characterize immunological changes in responders and nonresponders to AIT or biologics. This additional research may uncover new targets for monitoring treatment responses and developing personalized treatment strategies for allergic diseases.

查看原文本刊更多论文

过敏原免疫疗法和生物制剂在过敏性疾病中的作用。

过敏性疾病发病率的上升已成为全球性的健康负担。过敏性疾病是一组免疫介导的疾病，其特征是由IgE介导的2型辅助T细胞（Th2）偏斜免疫反应引起的疾病。本综述旨在全面总结过敏原免疫疗法（AIT）和生物制剂在过敏性疾病中作用的最新研究。具体来说，我们回顾了过敏原免疫疗法和生物制剂调节过敏性疾病发病机制中先天性和适应性免疫的机制，以及它们治疗过敏性疾病的安全性和有效性。我们还讨论了当前新的 AIT 策略，如基于过敏原的重组疫苗和过敏原提取物纳米封装。要了解 Th2 通路以外的免疫耐受机制，并描述对 AIT 或生物制剂有反应者和无反应者的免疫学变化，还需要进一步的研究。这些额外的研究可能会发现监测治疗反应和开发过敏性疾病个性化治疗策略的新目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.